241 related articles for article (PubMed ID: 20838384)
1. Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.
Kalra J; Sutherland BW; Stratford AL; Dragowska W; Gelmon KA; Dedhar S; Dunn SE; Bally MB
Oncogene; 2010 Dec; 29(48):6343-56. PubMed ID: 20838384
[TBL] [Abstract][Full Text] [Related]
2. Using Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo Model of Cancer.
Kalra J; Dragowska WH; Bally MB
J Histochem Cytochem; 2015 Sep; 63(9):691-709. PubMed ID: 25940338
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas.
Zhang YW; Zhao XX; Tan C; Zhang ZG; Jiang Y; Chen JN; Wei HB; Xue L; Li HG; Du H; Shao CK
Oncotarget; 2015 Jan; 6(1):207-20. PubMed ID: 25402957
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway.
Makino K; Day CP; Wang SC; Li YM; Hung MC
Oncogene; 2004 May; 23(21):3883-7. PubMed ID: 15021910
[TBL] [Abstract][Full Text] [Related]
5. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model.
Kalra J; Warburton C; Fang K; Edwards L; Daynard T; Waterhouse D; Dragowska W; Sutherland BW; Dedhar S; Gelmon K; Bally M
Breast Cancer Res; 2009; 11(3):R25. PubMed ID: 19409087
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
8. Integrin-linked kinase is dispensable for multiple myeloma cell survival.
Steinbrunn T; Siegmund D; Andrulis M; Grella E; Kortüm M; Einsele H; Wajant H; Bargou RC; Stühmer T
Leuk Res; 2012 Sep; 36(9):1165-71. PubMed ID: 22658851
[TBL] [Abstract][Full Text] [Related]
9. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells.
Basaki Y; Hosoi F; Oda Y; Fotovati A; Maruyama Y; Oie S; Ono M; Izumi H; Kohno K; Sakai K; Shimoyama T; Nishio K; Kuwano M
Oncogene; 2007 Apr; 26(19):2736-46. PubMed ID: 17072343
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of a novel integrin-linked kinase inhibitor.
Lee SL; Hsu EC; Chou CC; Chuang HC; Bai LY; Kulp SK; Chen CS
J Med Chem; 2011 Sep; 54(18):6364-74. PubMed ID: 21823616
[TBL] [Abstract][Full Text] [Related]
11. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).
Edwards LA; Woo J; Huxham LA; Verreault M; Dragowska WH; Chiu G; Rajput A; Kyle AH; Kalra J; Yapp D; Yan H; Minchinton AI; Huntsman D; Daynard T; Waterhouse DN; Thiessen B; Dedhar S; Bally MB
Mol Cancer Ther; 2008 Jan; 7(1):59-70. PubMed ID: 18202010
[TBL] [Abstract][Full Text] [Related]
12. Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells.
Ma JW; Hung CM; Lin YC; Ho CT; Kao JY; Way TD
Oncotarget; 2016 Sep; 7(37):58915-58930. PubMed ID: 27391337
[TBL] [Abstract][Full Text] [Related]
13. Twist induces epithelial-mesenchymal transition and cell motility in breast cancer via ITGB1-FAK/ILK signaling axis and its associated downstream network.
Yang J; Hou Y; Zhou M; Wen S; Zhou J; Xu L; Tang X; Du YE; Hu P; Liu M
Int J Biochem Cell Biol; 2016 Feb; 71():62-71. PubMed ID: 26693891
[TBL] [Abstract][Full Text] [Related]
14. Twist promotes tumor cell growth through YB-1 expression.
Shiota M; Izumi H; Onitsuka T; Miyamoto N; Kashiwagi E; Kidani A; Yokomizo A; Naito S; Kohno K
Cancer Res; 2008 Jan; 68(1):98-105. PubMed ID: 18172301
[TBL] [Abstract][Full Text] [Related]
15. Twist and p53 reciprocally regulate target genes via direct interaction.
Shiota M; Izumi H; Onitsuka T; Miyamoto N; Kashiwagi E; Kidani A; Hirano G; Takahashi M; Naito S; Kohno K
Oncogene; 2008 Sep; 27(42):5543-53. PubMed ID: 18504427
[TBL] [Abstract][Full Text] [Related]
16. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck.
Younes MN; Yigitbasi OG; Yazici YD; Jasser SA; Bucana CD; El-Naggar AK; Mills GB; Myers JN
Arch Otolaryngol Head Neck Surg; 2007 Jan; 133(1):15-23. PubMed ID: 17224516
[TBL] [Abstract][Full Text] [Related]
17. Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells.
Jung S; Ohk J; Jeong D; Li C; Lee S; Duan J; Kim C; Lim JS; Yang Y; Kim KI; Lee MS
Int J Oncol; 2014 Jul; 45(1):189-96. PubMed ID: 24789658
[TBL] [Abstract][Full Text] [Related]
18. Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models.
Becker-Santos DD; Guo Y; Ghaffari M; Vickers ED; Lehman M; Altamirano-Dimas M; Oloumi A; Furukawa J; Sharma M; Wang Y; Dedhar S; Cox ME
Carcinogenesis; 2012 Dec; 33(12):2558-67. PubMed ID: 23027626
[TBL] [Abstract][Full Text] [Related]
19. Integrin-linked kinase regulates integrin signaling in human trabecular meshwork cells.
Faralli JA; Newman JR; Sheibani N; Dedhar S; Peters DM
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1684-92. PubMed ID: 21071740
[TBL] [Abstract][Full Text] [Related]
20. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
Finkbeiner MR; Astanehe A; To K; Fotovati A; Davies AH; Zhao Y; Jiang H; Stratford AL; Shadeo A; Boccaccio C; Comoglio P; Mertens PR; Eirew P; Raouf A; Eaves CJ; Dunn SE
Oncogene; 2009 Mar; 28(11):1421-31. PubMed ID: 19151767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
